

Improving the Delivery of Value-Based Personalised Cancer Care Services

Public Event

Centre Health Policy | Seminar Series

Venue: Theatre 2, Alan Gilbert Building | 161 Barry Street, Carlton

Date: Thursday 22nd November 2018

Time: 2:00 - 3:30 PM | followed by refreshments

Enquiries: +61 3 8344 9111 | CHP-enquiries@unimelb.edu.au

Bookings: Free event, bookings required.

Professor Maarten IJzerman

Maarten J. IJzerman, MSc, PhD, is the VCCC professor and head of Cancer Health Services Research in the School of Population and Global Health, University of Melbourne. He also holds a fractional appointment as a professor in the University of Twente supervising PhD students working on the health economic impact of liquid biopsies in cancer management. He also is a co-PI of the Canadian-Dutch UCAN network, working on the application of precision medicine in juvenile arthritis. Maarten is a global leader in the International Society for Pharmacoeconomics and Outcomes Research, and as such promotes active collaboration between ISPOR and the European Cancer Organisation (ECCO) on systems analysis of value-based cancer care. In 2016, he joined the European Society for Medical Oncology (ESMO) Cancer Medicines working group dealing with the disparities in access to cancer drugs. Maarten is a board member of two Dutch hospitals, mainly responsible for quality and safety and strategy/innovation.



A recent publication from the Globocan consortium reported an increase to 18 million new cancer patients world-wide. While another large international consortium, i.e. the CONCORD, consistently reports improving survival rates, there is increasing concern about disparities in access to and outcomes of cancer services. As an example, the affordability of cancer drugs such as combination immunotherapy is an ongoing health policy concern.

Precision medicine applications offer the promise of improved risk assessment, earlier diagnosis and tailored treatment and survivorship care for cancer patients. However, despite significant investments and breakthroughs in genomics and precision medicine, successful translation into health services for the benefit of patients remains challenging. This presentation will discuss challenges in the translation of precision medicine applications in oncology. The presentation will then promote a systems perspective using real-world data rather than head-to-head clinical studies as an alternative for providing value-based cancer services.

